Mitochondrial biology in Alzheimer's disease pathogenesis.
Despite the increasing knowledge of Alzheimer's disease (AD) management with novel pharmacologic agents, most of them are only transiently fixing symptomatic pathology. Currently there is rapid growth in the field of neuroprotective pharmacology and increasing focus on the involvement of mitochondria in this devastating disease. This review is directed at understanding the role of mitochondria-mediated pathways in AD and integrating basic biology of the mitochondria with knowledge of possible pharmacologic targets for AD treatment in an attempt to elucidate novel mitochondria-driven therapeutic interventions useful to both clinical and basic research.
Galindo
María F
MF
Unidad de Neuropsicofarmacología Translacional, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
Ikuta
Ichiro
I
Zhu
Xiongwei
X
Casadesus
Gemma
G
Jordán
Joaquín
J
D000544:Alzheimer Disease / Q000209:etiology* / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D016229:Amyloid beta-Peptides / Q000009:adverse effects / Q000502:physiology; D000818:Animals; D006801:Humans; D008928:Mitochondria / Q000378:metabolism* / Q000473:pathology; D028361:Mitochondrial Diseases / Q000209:etiology* / Q000378:metabolism* / Q000473:pathology
D016229:Amyloid beta-Peptides